Rocky Mountain MS Clinic and Research Group Publications and Presentations

› Poster Presentation: Pharmacokinetic, immunological, and biochemical analysis in a natalizumab treated patient cohort

John F. Foley, MD

An open-label study of patients with relapsing forms of MS designed to assess the biochemical, immunicological, and pharmacokinetic profiles of a large, actively infusing natalizumab patient cohort. 

› Poster Presentation: The Efficacy of Natalizumab in Patients with Relapsing Multiple Sclerosis in a Clinical Practice Setting

John F. Foley, MD

The objective of this study was to evaluate the efficacy of natilizumab on the quality of life, neurologic function, and neuroradiographic study in patients with relapsing MS in a clinic practice setting. 

› Roundtable Discussion: MS Atrium Risk-Benefit

John F. Foley

MS Atrium

› Poster Presentation: Soluble Vascular Cell Adhesion Molecule (sVCAM) Levels and Herpes Zoster as Surrogate in Vivo Markers for Cell-Mediated Antiviral Immune Activity in a Natalizumab Treated MS Population

John F. Foley

63rd American Academy of Neurology (AAN) Annual Meeting

Apr 9, 2011 - Apr 16, 2011, Honolulu, Hawaii

The objective of this study was to identify markers related to increased risk of progressive multifocal leukoencephalopathy (PML) associated with natalizumab therapy which may aid in PML risk stratification.